Metabolic and drug-induced muscle disorders

Current Opinion in Neurology

Volumn 15, Issue 5, 2002, Pages 533-538

  Scarlato, Guglielmo ^a   Comi, Giacomo P ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Aetiology of Chanarin Dorfman syndrome; Beta enolase deficiency; Experimental murine models of glycogen storage disorders; Metabolic myopathies

Indexed keywords

ACYL COENZYME A DEHYDROGENASE; ALPHA GLUCOSIDASE; CARNITINE PALMITOYLTRANSFERASE; CERIVASTATIN; ENOLASE; ESTERASE; GLYCOGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; THIOL ESTER HYDROLASE; TRIACYLGLYCEROL LIPASE; UBIDECARENONE;

ANIMAL CELL; ANIMAL TISSUE; CASE REPORT; CGI 58 GENE; CHANARIN DORFMAN SYNDROME; CITRIC ACID CYCLE; CLINICAL TRIAL; DRUG INDUCED DISEASE; ENZYME DEFICIENCY; GENE EXPRESSION; GENE MUTATION; GENETIC DISORDER; GLYCOGEN STORAGE DISEASE; GLYCOGENOLYSIS; HUMAN; HYPERLIPIDEMIA; INFANT; LIPIDOSIS; METABOLIC DISORDER; MITOCHONDRIAL RESPIRATION; MOUSE; MUSCLE DISEASE; MUSCLE METABOLISM; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RESPIRATORY CHAIN; REVIEW; SYNDROME DELINEATION; TISSUE SPECIFICITY;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTILIPEMIC AGENTS; ANTIOXIDANTS; GLYCOGEN STORAGE DISEASE; HUMANS; LIPID METABOLISM; METABOLISM, INBORN ERRORS; MITOCHONDRIA, MUSCLE; MITOCHONDRIAL DISEASES; MUSCULAR DISEASES; MUTATION; PHOSPHOPYRUVATE HYDRATASE; UBIQUINONE;

EID: 0036796237     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-200210000-00003     Document Type: Review

References (62)

1. Di Mauro S, Lamperti C. Muscle glycogenoses. Muscle Nerve 2001; 24:984-999.
2. Fernandez-Hojas R, Huie ML, Navarro C, et al. Identification of six novel mutations in the acid alpha-glucosidase gene in three Spanish patients with infantile onset glycogen storage disease type II (Pompe disease). Neuromusc Disord 2002; 12:159-166.
3. Hadjigeorgiou GM, Papdimitriou A, Musumeci O, et al. A new stop codon mutation (Y52X) in the myophosphorylase gene in a Greek patient with McArdle's disease. J Neurol Sci 2002; 194:83-86.
4. Deschauer M, Opalka JR, Lindner A, Zierz S. A novel nonsense mutation (R269X) in the myophosphorylase gene in a patient with McArdle disease. Mol Genet Metab. 2001; 74:489-491.
5. Ausems MG, Wokke JH, Reuser AJ, van Diggelen OP. Juvenile and adult-onset acid maltase deficiency in France: genotype-phenotype correlation. Neurology 2001; 57:1938.
6. Comi GP, Fortunato F, Lucchiari S, et al. Beta-enolase deficiency, a new metabolic myopathy of distal glycolysis. Ann Neurol 2001; 50:202-207.
7. Bijvoet AG, Van de Kamp EH, Kroos MA, et al. Generalized glycogen storage and cardiomegaly in a knockout mouse model of Pompe disease. Hum Mol Genet 1998; 7:53-62.
8. Bijvoet AG, Van Hirtum H, Kroos MA, et al. Human acid alpha-glucosidase from rabbit milk has therapeutic effect in mice with glycogen storage disease type II. Hum Mol Genet 1999; 8:2145-2153.
9. Bijvoet AG, Van Hirtum H, Vermey M, et al. Pathological features of glycogen storage disease type II highlighted in the knockout mouse model. J Pathol 1999; 189:416-424.
10. Raben N, Nagaraju K, Lee E, et al. Targeted disruption of the acid alpha-glucosidase gene in mice causes an illness with critical features of both infantile and adult human glycogen storage disease type II. J Biol Chem 1999; 273:19086-19092.
11. Kamphoven JHJ, Stubenitsky R, Reuser AJJ, et al. Cardiac remodeling and contractile function in acid α-glucosidase knockout mice. Physiol Genom 2001; 5:171-179.
12. Van den Hout H, Reuser AJ, Vulto AG, et al. Recombinant human alpha-glucosidase from rabbit milk in Pompe patients. Lancet 2000; 356:397-398.
13. Amalfitano A, Bengur AR, Morse RP, et al. Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. Genet Med 2001; 3:132-138.
14. Raben N, Lu N, Nagaraju K, et al. Conditional tissue-specific expression of the acid α-glusidase (GAA) gene in the GAA knockout mice: implications for therapy. Hum Mol Gen 2001; 10:2039-2047.
15. Ding E, Hu H, Hodges BL, et al. Efficacy of gene therapy for a prototypical lysosomal storage disease (GSD-II) is critically dependent on vector dose, transgene promoter, and the tissues targeted for vector transduction. Mol Ther 2002; 5:436-446.
16. Raben N, Danon M, Lu N, et al. Surprises of genetic engineering. A possible model of polyglucosan body disease. Neurology 2001; 56:1739-1745.
17. Vockleya J, Whiteman D. Defects of mitochondrial β-oxidation: a growing group of disorders. Neuromusc Disord 2002; 12:235-246.
18. Wang Y, Korman SH, Ye J, et al. Phenotype and genotype variation in primary carnitine deficiency. Genet Med 2001; 3:387-392.
19. Ohashi R, Tamai I, Nezu J-I, et al. Molecular and physiological evidence for multifunctionality of carnitine/organic cation transporter OCTN2. Mol Pharmacol 2001; 59:358-366.
20. Nissenkorn A, Korman SH, Vardi O, et al. Carnitine-deficient myopathy as a presentation of tyrosinemia type I. J Child Neurol 2001; 16:642-644.
21. Lopriore E, Gemke RJ, Verhoeven NM, et al. Carnitine-acylcarnitine translocase deficiency: phenotype, residual enzyme activity and outcome. Eur J Pediatr 2001; 160:101-104.
22. Smolle KH, Kaufmann P, Gasser R. Recurrent rhabdomyolysis and acute respiratory failure due to carnitine palmityltransferase deficiency. Intens Care Med 2001; 27:1235.
23. Wallace RA, Klestov AC, Kubler PA. Emotional distress induced rhabdomyolysis in an individual with carnitine palmitoyl-transferase deficiency. Clin Exp Rheumatol 2001; 19:583-586.
24. Kottlors M, Jaksch M, Ketelsen UP, et al. Valproic acid triggers acute rhabdomyolysis in a patient with carnitine palmitoyltransferase type II deficiency. Neuromusc Disord 2001; 11:757-759.
25. Gempel K, von Praun C, Baumkotter J, et al. 'Adult' form of muscular carnitine palmitoyltransferase II deficiency: manifestation in a 2-year-old child. Eur J Pediatr 2001; 160:548-551.
26. Elpeleg ON, Hammerman C, Saada A, et al. Antenatal presentation of carnitine palmitoyltransferase II deficiency. Am J Med Genet 2001; 102:183-187.
27. Wood JC, Magera MJ, Rinaldo P, et al. Diagnosis of very long chain acyldehydrogenase deficiency from an infant's newborn screening card. Pediatrics 2001; 108:E19.
28. Fukao T, Watanabe H, Orii K, et al. Myopathic form of very-long chain acyl-CoA dehydrogenase deficiency: evidence for temperature-sensitive mild mutations in both mutant alleles in a Japanese girl. Pediatr Res 2001; 49:227-231.
29. Miyajima H, Ouchi Y, Sakamoto M, et al. Increased anaerobic glycolysis in mitochondrial trifunctional protein-deficient brain. J Neurol Sci 2001; 184:197-201.
30. Onkenhout W, Venizelos V, Scholte HR, et al. Intermediates of unsaturated fatty acid oxidation are incorporated in triglycerides but not in phospholipids in tissues from patients with mitochondrial beta-oxidation defects. J Inherit Metab Dis 2001; 24:337-344.
31. Lefevre C, Jobard F, Caux F, et al. Mutations in CGI-58, the gene encoding a new protein of the esterase/lipase/thioesterase subfamily, in Chanarin-Dorfman syndrome. Am J Hum Genet 2001; 69:1002-1012.
32. Schlame M, Towbin JA, Heerdt PM, et al. Deficiency of tetralinoleoyl-cardiolipin in Barth syndrome. Ann Neurol 2002; 51:634-637.
33. Zeviani M, Klopstock T. Mitochondrial disorders. Curr Opin Neurol 2001; 14:553-560.
34. Seneca S, Verhelst H, De Meirleir L, et al. A new mitochondrial point mutation in the transfer RNA(Leu) gene in a patient with a clinical phenotype resembling Kearns-Sayre syndrome. Arch Neurol 2001; 58:1113-1118.
35. Nagashima T, Kato H, Maguchi S, et al. A mitochondrial encephalo-myoneuropathy with a nucleotide position 3271 (T-C) point mutation in the mitochondrial DNA. Neuromusc Disord 2001; 11:470-476.
36. Campos Y, Gamez J, Garcia A, et al. A new mtDNA mutation in the tRNA(Leu(UUR)) gene associated with ocular myopathy. Neuromusc Disord 2001; 11:477-480.
37. Spagnolo M, Tomelleri G, Vattemi G, et al. A new mutation in the mitochondrial tRNA(Ala) gene in a patient with ophthalmoplegia and dysphagia. Neuromusc Disord 2001; 11:481-484.
38. Nishigaki Y, Bonilla E, Shanske S, et al. Exercise-induced muscle 'burning', fatigue, and hyper-CKemia: mtDNA T10010C mutation in tRNA(Gly). Neurology 2002; 58:1282-1285.
39. Taylor RW, Singh-Kler R, Hayes CM, et al. Progressive mitochondrial disease resulting from a novel missense mutation in the mitochondrial DNA ND3 gene. Ann Neurol 2001; 50:104-107.
40. Taylor RW, Morris AA, Hutchinson M, Turnbull DM. Leigh disease associated with a novel mitochondrial DNA ND5 mutation. Eur J Hum Genet 2002; 10:141-144.
41. Campos Y, Garcia-Redondo A, Fernandez-Moreno MA, et al. Early-onset multisystem mitochondrial disorder caused by a nonsense mutation in the mitochondrial DNA cytochrome C oxidase II gene. Ann Neurol 2001; 50:409-413.
42. Lamantea E, Carrara F, Mariotti C, et al. A novel nonsense mutation (Q352X) in the mitochondrial cytochrome b gene associated with a combined deficiency of complexes I and III. Neuromusc Disord 2002; 12:49-52.
43. Wibrand F, Ravn K, Schwartz M, et al. Multisystem disorder associated with a missense mutation in the mitochondrial cytochrome b gene. Ann Neurol 2001; 50:540-543.
44. Zeviani M, Servidei S, Gellera C, et al. An autosomal dominant disorder with multiple deletions of mitochondrial DNA starting at the D-loop region. Nature 1989; 339:309-311.
45. Nishino I, Spinazzola A, Hirano M. Thymidine phosphorylase gene mutations in MNGIE, a human mitochondrial disorder. Science 1999; 283:689-692.
46. Kaukonen J, Zeviani M, Comi GP, et al. A third locus predisposing to multiple deletions of mtDNA in autosomal dominant progressive external ophthalmoplegia. Am J Hum Genet 1999; 65:256-261.
47. Suomalainen A, Kaukonen J, Amati P, et al. An autosomal locus predisposing to deletions of mitochondrial DNA. Nat Genet 1995; 9:146-151.
48. Van Goethem G, Dermaut B, Lofgren A, et al. Mutation of POLG is associated with progressive external ophthalmoplegia characterized by mtDNA deletions. Nat Genet 2002; 28:211-212.
49. Kaukonen J, Juselius JK, Tiranti V, et al. Role of adenine nucleotide translocator 1 in mtDNA maintenance. Science 2000; 289:782-785.
50. Napoli L, Bordoni A, Zeviani M, et al. A novel missense adenine nucleotide translocator-1 gene mutation in a Greek adPEO family. Neurology 2001; 57:2295-2298.
51. Spelbrink JN, Li FY, Tiranti V, et al. Human mitochondrial DNA deletions associated with mutations in the gene encoding Twinkle, a phage T7 gene 4-like protein localized in mitochondria. Nat Genet 2001; 28:223-231.
52. Saada A, Shaag A, Mandel H, et al. Mutant mitochondrial thymidine kinase in mitochondrial DNA depletion myopathy. Nat Gen 2001; 29:342-344.
53. Mandel H, Szargel R, Labay V. The deoxyguanosine kinase gene is mutated in individuals with depleted hepatocerebral mitochondrial DNA. Nat Genet 2001; 29:337-341.
54. de Lonlay P, Valnot I, Barrientos A, et al. A mutant mitochondrial respiratory chain assembly protein causes complex III deficiency in patients with tubulopathy, encephalopathy and liver failure. Nat Genet 2001; 29:57-60.
55. Di Giovanni S, Mirabella M, Spinazzola A, et al. Coenzyme Q10 reverses pathological phenotype and reduces apoptosis in familial CoQ10 deficiency. Neurology 2001; 57:515-518.
56. Hodel C. Myopathy and rhabdomyolysis with lipid-lowering drugs. Toxicol Lett 2002; 128:159-168.
57. Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 2002; 346:539-540.
58. Garcia-Valdecasas-Campelo GE, Gonzalez-Reimers E, Lopez-Lirola A, et al. Acute rhabdomyolysis associated with cerivastatin therapy. Arch Med 2001; 161:893.
59. Giner V, Munoz R, Redon J. Risperidone and severe cerivastatin-induced rhabdomyolysis. J Intern Med 2002; 251:177-178.
60. Furneg CD, Pitt B. Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med 2001; 2:205-207.
61. American Heart Association and American College of Cardiology Advisory. ACC and AHA reassure patients about statins' effectiveness, safety. Physician urged to discuss concerns side effects and options for lowering cholesterol. News Release. 30 August 2001. [http://www.americanheart.org/Whats_news/AHA_News_Releases/ 30Aug3001100715_01.htlm].
62. Pierno S, De Luca A, Tricarico D, et al. Experimental evaluation of the effects of pravastatin on electrophysiological parameters of rat skeletal muscle. Pharmacol Toxicol 1992; 71:325-329.